← Leaderboards
Yaguang Xi
Southeast Louisiana Veterans Health Care
$6,543,348
Attributed
$7,212,134
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,212,134 · 6
VA$0 · 1
By mechanism
R01$6,508,983 · 4
R21$703,151 · 2
I01$0 · 1
Top collaborators
- Qingzhao Yu3 shared
- Gary A Piazza2 shared
Others in their field
Top investigators on “United States”
- Leonard Freedman · Leidos Biomedical Research, Inc.$818,172,357
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$638,373,375
- David Heimbrook · Leidos Biomedical Research, Inc.$632,657,800
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United StatesTumorMicrornasAnimal ModelMalignant NeoplasmsIncidenceSulindacToxic EffectPharmaceutical PreparationsMediatingNeoplasm MetastasisReportingMouse ModelCancer PatientIn VivoBiological MarkersOncogenicBreast Cancer CellCause Of DeathClinical TrialsTumor ProgressionMolecularNon-Steroidal Anti-Inflammatory AgentsGenes
Grant awards (27)
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer$756,324
R01 · FY2025 · CA · contact PI
Interactions between ES-miRNAs and environmental risk factors are responsible for TNBC progression and associated racial health disparities: a novel analysis with multilevel moderation inferences$336,263
R01 · FY2025 · CA
MiR-17 mediates sulindac anti-metastatic activity in human colorectal cancer$0
I01 · FY2025 · VA · contact PI
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy$533,414
R01 · FY2024 · CA · contact PI
Interactions between ES-miRNAs and environmental risk factors are responsible for TNBC progression and associated racial health disparities: a novel analysis with multilevel moderation inferences$319,450
R01 · FY2024 · CA
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer$1
R01 · FY2024 · CA · contact PI
MiR-17 mediates sulindac anti-metastatic activity in human colorectal cancer$0
I01 · FY2024 · VA · contact PI
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy$563,009
R01 · FY2023 · CA · contact PI
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer$384,041
R01 · FY2023 · CA · contact PI
Interactions between ES-miRNAs and environmental risk factors are responsible for TNBC progression and associated racial health disparities: a novel analysis with multilevel moderation inferences$336,263
R01 · FY2023 · CA
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy$553,817
R01 · FY2022 · CA · contact PI
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer$373,869
R01 · FY2022 · CA · contact PI
Investigate interactive roles of environmental, behavioral and genetic factors on racial disparities in breast cancer outcomes$110,250
R01 · FY2022 · CA · contact PI
MiR-17 mediates sulindac anti-metastatic activity in human colorectal cancer$0
I01 · FY2022 · VA · contact PI
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer$381,499
R01 · FY2021 · CA · contact PI
MicroRNA and colorectal cancer chemoprevention$323,955
R01 · FY2019 · CA · contact PI
MicroRNA and colorectal cancer chemoprevention$92,880
R01 · FY2019 · CA · contact PI
MicroRNA and colorectal cancer chemoprevention$333,975
R01 · FY2018 · CA · contact PI
MicroRNA and colorectal cancer chemoprevention$95,753
R01 · FY2018 · CA · contact PI
MicroRNA and colorectal cancer chemoprevention$333,975
R01 · FY2017 · CA · contact PI
MicroRNA and colorectal cancer chemoprevention$333,975
R01 · FY2016 · CA · contact PI
MicroRNA and colorectal cancer chemoprevention$346,270
R01 · FY2015 · CA · contact PI
MicroRNA, a new player for the NSAID sulindac to prevent colon cancer progression$113,430
R21 · FY2015 · CA · contact PI
MicroRNA, a new player for the NSAID sulindac to prevent colon cancer progression$47,069
R21 · FY2015 · CA · contact PI
MicroRNA, a new player for the NSAID sulindac to prevent colon cancer progression$197,055
R21 · FY2014 · CA · contact PI
MicroRNA, sulindac, and breast cancer chemoprevention$151,804
R21 · FY2013 · CA · contact PI
MicroRNA, sulindac, and breast cancer chemoprevention$193,793
R21 · FY2012 · CA · contact PI